MaxCyte (MXCT) Stock: Buy, Sell, or Hold?
MXCT - MaxCyte, Inc. Common Stock
$1.16
-0.03 (-2.52%)
▼
5d:
-7.94%
30d:
-8.66%
90d:
+5.45%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When MXCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: MXCT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: MXCT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: MXCT is currently trading at $1.16, which is considered oversold relative to its 30-day fair value range of $1.19 to $1.35.
Technical Outlook: Technically, MXCT is in a strong downtrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MXCT scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.11 (+254.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MXCT is in a strong downtrend. The price is currently testing key support at $1.16. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: MXCT scores 23/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $4.11 (+254.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$1.19 -
$1.35
Company Quality Score
37/100
(SELL)
Options IV Signal
46th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
60.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 46th percentile)
- BEARISH: Weak technical setup (23/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 254.1% below Wall St target ($4.11)
- WARNING: Composite score 37/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.19 -
$1.35
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.50
(43.5%)
Support & Resistance Levels
Support Level
$1.16
Resistance Level
$1.32
Current Trend
Strong Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.73
Wall Street Target
$4.11
(+254.1%)
Revenue Growth (YoY)
-14.5%
Profit Margin
-114.8%
Share & Embed Analysis
Last updated: September 13, 2026 9:27 PM ET
Data refreshes hourly during market hours. Next update: 10:27 PM
Data refreshes hourly during market hours. Next update: 10:27 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MXCT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$62 | 49 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
27 analysts |
$94 | 40 HOLD |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$376 | 44 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
